We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Structure of presentation
- Retroviruses for gene transfer
- Evolutionary optimized gene carriers
- Retroviral entry: intracellular highways preferred
- Retroviruses are evolutionary adapted to cells
- The biology of retroviruses
- Phylogeny of retroviruses
- Genome and particle retroviral organization (1)
- Genome and particle retroviral organization (2)
- From the virus to the vector
- Pseudotyping retroviral vectors
- Clinical applications of gene and cell therapy
- Blood, a very special juice
- Gene therapy: effective but with side effects
- Gene therapy for ADA-SCID (1)
- Gene therapy for ADA-SCID (2)
- X-SCID
- Gene therapy for X-SCID (1)
- Gene therapy for X-SCID (2)
- Safer vector design for gene therapy of X-SCID
- Severe adverse events after gene therapy
- Modes of insertional mutagenesis
- Prevention of insertional mutagenesis (1)
- Prevention of insertional mutagenesis (2)
- Gammaretroviral LTR vs. SIN vectors (1)
- Gammaretroviral LTR vs. SIN vectors (2)
- Determining the risk of insertional transformation
- Assays to analyze different vector configurations
- Cellular promoters are weak activators
- IVIM assay
- Improved vectors lead to increased survival
- Right therapeutic window for gene therapy
- T cell applications: chimeric antigen receptors
- Alpharetroviral SIN vectors
- Synthetic, clean split-packaging system
- Alpharetroviral vectors transduce murine HSC
- Transduction of clinically relevant human cells
- Integration pattern of SIN vectors in CD34+ HSCs
- Intermediate stages of retroviral replication (1)
- Intermediate stages of retroviral replication (2)
- Intermediate stages of retroviral replication (3)
- Intermediate stages of retroviral replication (4)
- A time journey: the beginning of gene therapy
- BMT after 1957
- Gene therapy – where is the field currently?
- Glybera - first gene therapy drug on the EU market
- Summary and take home message
- Acknowledgements
Topics Covered
- The biology of retroviruses: genome & particle organization, retroviral life cycle
- Retroviruses as evolutionary adapted vehicles to deliver genetic information
- From the virus to the retroviral vector
- Effective gene therapy in the clinical arena
- Adverse events and prevention of insertional mutagenesis
- SIN vectors and the right therapeutic window for gene therapy
- Developing retroviral intermediates as delivery tools
- A time journey in the field of retroviral gene therapy
Talk Citation
Schambach, A. (2014, November 6). Gammaretroviral vectors: biology, design and applications [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 9, 2024, from https://doi.org/10.69645/JPOG3284.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Axel Schambach has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Gammaretroviral vectors: biology, design and applications
A selection of talks on Genetics & Epigenetics
Transcript
Please wait while the transcript is being prepared...
0:00
Hello.
My name is Axel Schambach,
and I'm the acting director
of the Institute of
Experimental Hematology
at Hannover Medical School.
Within the next 40
to 45 minutes or so,
I would like to give
you a broad overview
on gammaretroviral vectors,
their biology, their design,
and their applications
in clinical trials.
0:23
I will structure my
presentation as follows.
I will start with an introduction
into the biology of retroviruses,
including their genome
and particle organization
and the retroviral life cycle.
From there I will give some insights
how retroviruses have developed
as evolutionary adapted vehicles
to deliver genetic information.
As a next step, we will
convert a retrovirus
into the retroviral
vector gene delivery tool
and mention how this vector
system has been efficiently used
in the clinical gene therapy arena.
We will also touch the
occurred adverse events
and how these would
potentially be prevented
in future gene therapy trials.
And mention the
development of SIN vectors
and how to create the
right therapeutic window
for gene therapy.
Apart from the integrating
retroviral vectors,
we will also mention
retroviral intermediates
as delivery tools for
genetic information.
And also in the end take you
a little bit on a time journey
into the field of retroviral gene
therapy and how it has developed.
Finally, I will conclude with a
summary and a take-home message.
1:30
So let's go into the details.
So what's so special about
retroviruses that makes them
attractive tools for gene transfer?
So first of all, retroviruses
are evolutionary optimized gene
carriers that have naturally
adapted to their host to efficiently
deliver genetic information
into target cells.
And as a hallmark and
common to all retroviruses,
they have the stage of
reverse transcription
of their single-stranded RNA
genome into double-stranded DNA.
And this double-stranded
DNA is then stably
integrated into the
host cell genome.
Looking back, they are highly
evolved parasites which exploit
the host cell machinery
for their own replication.
And it's maybe a
little bit surprising
to know that retroviruses are
already more than 8 million years
old and have been found already
back then in the mammalian genome.
The first approaches have been put
forward using retrovirus-based gene
transfer approximately 30 years ago.
Back then it has been shown that
it's much more efficient than DNA
transfection in primary cells
and that their use in murine bone
marrow transplantation
was quite successful
and paved the way for gene therapy
of the hematopoietic system.